	US 12,115,260 B2
	Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
Thomas Gottstein, Babenhausen (DE); Guenter Knaup, Bruchkoebel (DE); and Michael Schwarm, Alzenau (DE)
Assigned to Evonik Operations GmbH, Essen (DE)
Appl. No. 16/304,178
Filed by Evonik Operations GmbH, Essen (DE)
PCT Filed May 24, 2017, PCT No. PCT/EP2017/062592 § 371(c)(1), (2) Date Nov. 23, 2018, PCT Pub. No. WO2017/202942, PCT Pub. Date Nov. 30, 2017.
Claims priority of application No. 16171296 (EP), filed on May 25, 2016.
Prior Publication US 2020/0315970 A1, Oct. 8, 2020
Int. Cl. A61K 9/20 (2006.01); A23L 33/115 (2016.01); A23L 33/17 (2016.01); A61K 31/198 (2006.01); A61K 31/202 (2006.01)

CPC A61K 9/2027 (2013.01) [A23L 33/115 (2016.08); A23L 33/17 (2016.08); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2095 (2013.01); A61K 31/198 (2013.01); A61K 31/202 (2013.01)]

23 Claims

1. A tablet, comprising:

eicosapentaenoic acid combined with a first basic amino acid as an EPA salt;

docosahexaenoic acid combined with a second basic amino acid as a DHA salt;

a total amount of 20 wt. % or less, based on a total tablet weight, of a binder and/or a structure-forming substance selected from the group consisting of polyvinylpyrrolidone, starch, lactose, microcrystalline cellulose, calcium sulfate, mannitol, calcium phosphate, and a mixture thereof,

wherein the EPA and DHA salts are present as a mixture in powder form, and

wherein a sum of the eicosapentaenoic acid and the docosahexaenoic acid in the tablet is 40 wt. % or more, based on the total tablet weight and measured in free acid form.